Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin

Translational Research

Volumn 165, Issue 5, 2015, Pages 558-577

  Saha, Shilpi ^a   Mukherjee, Shravanti ^a   Mazumdar, Minakshi ^a   Manna, Argha ^a   Khan, Poulami ^a   Adhikary, Arghya ^a,d   Kajal, Kirti ^a   Jana, Debarshi ^b   Sa, Gaurisankar ^a   Mukherjee, Sanhita ^c   Sarkar, Diptendra K ^b   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c BANKURA SAMMILANI MEDICAL COLLEGE   (India)

^d UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; MITHRAMYCIN; MITHRAMYCIN A; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; SP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER STEM CELL; CELL RENEWAL; CLINICAL ARTICLE; DNA DAMAGE; DRUG SENSITIZATION; GENOTOXICITY; HUMAN; HUMAN CELL; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL FACTOR; TUMOR MICROENVIRONMENT; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; MULTICELLULAR SPHEROID; PATHOLOGY; TRANSLATIONAL RESEARCH; TUMOR CELL CULTURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PLICAMYCIN; SP1 TRANSCRIPTION FACTOR; SPHEROIDS, CELLULAR; TRANSLATIONAL MEDICAL RESEARCH; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84927911295     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.10.011     Document Type: Article

References (72)

1. T. Yi, B. Zhai, and Y. Yu Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells Proc Natl Acad Sci U S A 111 2014 E2182 E2190
2. V.V. Valero, A.U. Buzdar, and G.N. Hortobagyi Locally advanced breast cancer Oncologist 1 1996 8 17
3. S.E. Singletary, C. Allred, and P. Ashley Revision of the American Joint Committee on Cancer staging system for breast cancer J Clin Oncol 20 2002 3628 3636
4. J. Specht, and J.R. Gralow Neoadjuvant chemotherapy for locally advanced breast cancer Semin Radiat Oncol 19 2009 222 228
5. S.V. Liu, L. Melstrom, K. Yao, C.A. Russell, and S.F. Sener Neoadjuvant therapy for breast cancer J Surg Oncol 101 2010 283 291
6. S. Cleator, M. Parton, and M. Dowsett The biology of neoadjuvant chemotherapy for breast cancer Endocr Relat Cancer 9 2002 183 195
7. E.P. Mamounas Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer 4 2003 s10 s19
8. S. Sinclair, and S.M. Swain Primary systemic chemotherapy for inflammatory breast cancer Cancer 116 2010 s2821 s2828
9. A. Singh, and J. Settleman Cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 29 2010 4741 4751
10. C.E. Eyler, and J.N. Rich Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis J Clin Oncol 26 2008 2839 2845
11. S.W. Crowder, D.A. Balikov, Y.S. Hwang, and H.J. Sung Cancer stem cells under hypoxia as a chemoresistance factor in breast and brain Curr Pathobiol Rep 2 2014 33 40
12. M. Diehn, R.W. Cho, and N.A. Lobo Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 2009 780 783
13. C.S. O'Brien, G. Farnie, S.J. Howell, and R.B. Clarke Breast cancer stem cells and their role in resistance to endocrine therapy Horm Cancer 2 2011 91 103
14. X. Li, M.T. Lewis, and J. Huang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 2008 672 679
15. C.J. Creighton, X. Li, and M. Landis Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci U S A 106 2009 13820 13825
16. T. Tanei, K. Morimoto, and K. Shimazu Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers Clin Cancer Res 15 2009 4234 4241
17. - phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma J Exp Clin Cancer Res 31 2012 59
18. M. Alamgeer, V. Ganju, and B. Kumar Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer Breast Cancer Res 16 2014 R44
19. K. Moitra, H. Lou, and M. Dean Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development Clin Pharmacol Ther 89 2011 491 502
20. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 2014 48 58
21. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 2000 265 283
22. W.J. Yang, M.J. Song, and E.Y. Park Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype Mol Cells 36 2013 368 375
23. J. Li, X. Wu, and J. Gong Vascular endothelial growth factor induces multidrug resistance-associated protein 1 overexpression through phosphatidylinositol-3-kinase/protein kinase B signaling pathway and transcription factor specificity protein 1 in BGC823 cell line Acta Biochim Biophys Sin (Shanghai) 45 2013 656 663
24. K.W. Scotto Transcriptional regulation of ABC drug transporters Oncogene 22 2003 7496 7511
25. S. Safe, and M. Abdelrahim Sp1 transcription factor family and its role in cancer Eur J Cancer 41 2005 2438 2448
26. N. Kolesnikoff, J.L. Attema, and S. Roslan Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition J Biol Chem 289 2014 11194 11205
27. M. Abdelrahim, R. Smith III, R. Burghardt, and S. Safe Role of Sp1 proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells Cancer Res 64 2004 6740 6749
28. X.B. Wang, W.Q. Peng, Z.J. Yi, S.L. Zhu, and Q.H. Gan Expression and prognostic value of transcriptional factor Sp1 in breast cancer Ai Zheng 26 2007 996 1000
29. Y. Zhao, W. Zhang, and Z. Guo Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts Oncol Rep 30 2013 1782 1792
30. M. Zhang, A. Mathur, and Y. Zhang Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells Cancer Res 72 2012 4178 4192
31. S. Chatterjee, K. Zaman, H. Ryu, A. Conforto, and R.R. Ratan Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons Ann Neurol 49 2001 345 354
32. S.F. Leiman, B.C. Langley, and M. Basso Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration J Neurosci 31 2011 6858 6870
33. O.H. Beahrs, D.E. Henson, and R.V.P. Hutter Handbook for staging of cancer. From the manual for staging on cancer 4th ed. 1993 J.B. Lippincott Philadelphia 161 167
34. H.M. Kuerer, L.A. Newman, and T.L. Smith Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460 469
35. A.U. Buzdar Preoperative chemotherapy treatment of breast cancer - a review Cancer 110 2007 2394 2407
36. B.K. Arun, K. Dhinghra, and V. Valero Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results Oncologist 16 2011 1527 1534
37. T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, L. Reyno Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer Clinical practice guidelines for the care and treatment of breast cancer: treatment for women with stage III or locally advanced breast cancer CMAJ 170 2004 983 994
38. M.E. Hammond, D.F. Hayes, and M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med 134 2010 e48 e72
39. T.M. Prowell, and R. Pazdur Pathological complete response and accelerated drug approval in early breast cancer N Engl J Med 366 2012 2438 2441
40. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
41. G. Dontu, W.M. Abdallah, and J.M. Foley In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells Genes Dev 17 2003 1253 1270
42. -/low breast cancer stem cells and axillary lymph node metastasis J Transl Med 10 Suppl 1 2012 S6
43. S. Mohanty, S. Saha, and D. Md S Hossain ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors Cell Death Dis 5 2014 e1021
44. C.M. Fillmore, and C. Kuperwasser Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy Breast Cancer Res 10 2008 R25
45. S. Saha, P. Bhattacharjee, and S. Mukherjee Contribution of the ROS-p53 feedback loop in thuja-induced apoptosis of mammary epithelial carcinoma cells Oncol Rep 31 2014 1589 1598
46. F. Shen, S. Chu, and A.K. Bence Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells J Pharmacol Exp Ther 324 2008 95 102
47. A. Adhikary, S. Chakraborty, and M. Mazumdar Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of SMAR1 in breast cancer cells J Biol Chem 289 2014 25431 25444
48. M. Mazumdar, A. Adhikary, and S. Chakraborty Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways Apoptosis 18 2013 589 604
49. S. Chakraborty, K. Das, and S. Saha Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone de-acetylation J Biol Chem 289 2014 29074 29085
50. S.J. Potts, J.S. Krueger, and N.D. Landis Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue Lab Invest 92 2012 1342 1357
51. A.D. Hartkopf, F.A. Taran, and M. Wallwiener The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy Breast Cancer Res 15 2013 R94
52. C.A. Koller, and D.M. Miller Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea N Engl J Med 315 1986 1433 1438
53. M. Pardo, B. Lang, and L. Yu An expanded Oct4 interaction network: implications for stem cell biology, development, and disease Cell Stem Cell 6 2010 382 395
54. H.M. Yang, H.J. Do, and J.H. Oh Characterization of putative cis-regulatory elements that control the transcriptional activity of the human Oct4 promoter J Cell Biochem 96 2005 821 830
55. D.Y. Wu, and Z. Yao Functional analysis of two Sp1/Sp3 binding sites in murine Nanog gene promoter Cell Res 16 2006 319 322
56. H. Mizutani, S. Tada-Oikawa, Y. Hiraku, M. Kojima, and S. Kawanishi Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide Life Sci 76 2005 1439 1453
57. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
58. S.C. Linn, H.M. Pinedo, and J. van Ark-Otte Expression of drug resistance proteins in breast cancer, in relation to chemotherapy Int J Cancer 71 1997 787 795
59. K.H. Koga, S.M. Moriguchi, and G. Uemura Monitoring the response to neoadjuvant chemotherapy in breast cancer 2013 nTech Rijeka, Croatia (http://dx.doi.org/10.5772/53123)
60. E. Montagna, V. Bagnardi, and N. Rotmensz Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer Br J Cancer 98 2008 1745 1752
61. L. Gianni, J. Baselga, and W. Eiermann Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer J Clin Oncol 27 2009 2474 2481
62. M. Dowsett, C. Allred, and J. Knox Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial J Clin Oncol 26 2008 1059 1065
63. D.E. Linn, X. Yang, and F. Sun A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells Genes Cancer 1 2010 908 916
64. X.Q. Wang, W.M. Ongkeko, and L. Chen Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway Hepatology 52 2010 528 539
65. Y. Huang, B. Ju, and J. Tian Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening Oncol Rep 31 2014 1235 1248
66. S. Boichuk, D.J. Lee, and K.R. Mehalek Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors Cancer Res 74 2014 1200 1213
67. M. Signore, L. Ricci-Vitiani, and R. De Maria Targeting apoptosis pathways in cancer stem cells Cancer Lett 332 2013 374 382
68. L. Chen, and L.Y. Bourguignon Hyaluronan-CD44 interaction promotes c-Jun signalling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells Mol Cancer 13 2014 52
69. C. Vyhlidal, I. Samudio, M.P. Kladde, and S. Safe Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site J Mol Endocrinol 24 2000 329 338
70. T.J. Lee, E.M. Jung, and J.T. Lee Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites Mol Cancer Ther 5 2006 2737 2746
71. J. Seznec, B. Silkenstedt, and U. Naumann Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma J Neurooncol 101 2011 365 377
72. A. Ludin, S. Gur-Cohen, and K. Golan Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration, and development, as well as their bone marrow microenvironment Antioxid Redox Signal 21 2014 1605 1619